Gene Techno Science Co., Ltd.

Astellas Pharma Gmbh

Kaken Pharmaceutical Company, Ltd.

Juridical Foundation the Chemo-sero-therapeutic Research Institute

Shigeyuki Kon

Toshimitsu Uede

Naoya Tsurushita

J Yun Tso

Shankar Kumar

Masashi Kanayama

Daisuke Kurotaki

Hiroaki Maeda

Toshihiro Nakashima

Masaharu Torikai

Hirofumi Higuchi

Nobuchika Yamamoto

Chiemi Kimura

Yoshiyuki Tokieda

The present invention relates to an anti-human &#x3b1;9 integrin antibody. More particularly, the present invention relates to: a monoclonal antibody, a chimeric antibody, a humanized antibody and a human antibody that specifically recognize human &#x3b1;9 integrin; a hybridoma cell that produces the monoclonal antibody; a method for producing the monoclonal antibody; a method for producing the hybridoma cell; a therapeutic agent comprising the anti-human &#x3b1;9 integrin antibody; a diagnostic agent comprising the human &#x3b1;9 integrin antibody; and a method for screening for a compound that inhibits the activity of human &#x3b1;9 integrin.

Anti-human &#x3b1;9 integrin antibody and use thereof

The present invention provides a monoclonal antibody which specifically recognizes RGD in the amino acid sequence of extracellular matrix proteins of a human and a mouse. By specifically inhibiting the RGD sequence-mediated adhesion, exertion of efficient effects on diseases such as inflammation, cancer, infectious disease, autoimmune diseases and osteoporosis and reduction in adverse effects can be expected at the same time. Therefore, better treatment methods can be provided to these diseases.

Antibody against RGD in amino acid sequence of extracellular matrix protein and production method and use of the same

The present invention provides humanized antibodies that immunospecifically recognize human &#x3b1;9 integrin. Some of these antibodies inhibit the biological functions of the &#x3b1;9 integrin, thereby exhibiting therapeutic effects on various disorders or diseases that are associated with &#x3b1;9 integrin, including cancer, e.g., the growth and metastasis of a cancer cell, and inflammatory diseases, e.g., rheumatoid arthritis, osteoarthritis, hepatitis, bronchial asthma, fibrosis, diabetes, arteriosclerosis, multiple sclerosis, granuloma, an inflammatory bowel disease (ulcerative colitis and Crohn's disease), an autoimmune disease, and so forth.

Humanized anti-&#x3b1; 9 integrin antibodies and the uses thereof

The present invention provides humanized antibodies that immunospecifically recognize the RGD sequence. Some of these antibodies inhibit the biological functions of the RGD proteins, thereby exhibiting therapeutic effects on various disorders or diseases that are associated with RGD proteins, including cancer, e.g., the growth and metastasis of a cancer cell, and inflammatory diseases, e.g., rheumatoid arthritis, osteoarthritis, hepatitis, endometriosis, bronchial asthma, fibrosis, diabetes, arteriosclerosis, multiple sclerosis, granuloma, an inflammatory bowel disease (ulcerative colitis and Crohn's disease), an autoimmune disease, and so forth.

Humanized antibodies specific for amino acid sequence RGD of an extracellular matrix protein and the uses thereof

The present invention relates to: an antibody, particularly a monoclonal antibody, a chimeric antibody, a humanized antibody and a human antibody, which specifically recognize human &#x3b1;9 integrin; a hybridoma cell which produces the monoclonal antibody; a method for producing the monoclonal antibody; a method for producing the hybridoma cell; a therapeutic agent comprising the anti-human &#x3b1;9 integrin antibody; a diagnostic agent comprising the human &#x3b1;9 integrin antibody; and a method for screening a compound which inhibits the activity of human &#x3b1;9 integrin.

Antihuman &#x3b1;9 integrin antibody and use of the same

The present invention provides an anti-mouse &#x3b1;9 integrin antibody, an anti-human &#x3b1;9 integrin antibody, a hybridoma producing any of the antibodies, a method of producing any of the antibodies and the hybridoma, and a pharmaceutical composition comprising any of the antibodies. The anti-&#x3b1;9 integrin antibody of the present invention inhibits the &#x3b1;9 integrin function thereby to exhibit therapeutic effects on cancer, e.g., the growth and metastasis of a cancer cell, and an inflammatory disease, e.g., rheumatoid arthritis, osteoarthritis, hepatitis, bronchial asthma, fibrosis, diabetes, arteriosclerosis, multiple sclerosis, granuloma, an inflammatory bowel disease (ulcerative colitis and Crohn's disease), an autoimmune disease and the like.

Anti-&#x3b1;9 integrin antibody and the use thereof

A recombinant antibody in which at least the constant regions in the heavy chain and the light chain have been converted into human-origin regions and which inhibits the binding of an integrin recognizing the RGD sequence to osteopontin or its fragment and inhibits the binding of an integrin recognizing the SVVYGLR sequence or a sequence corresponding thereto to osteopontin or its fragment. This antibody is useful as a remedy for autoimmune diseases and a remedy for rheumatism or rheumatoid arthritis. Thus, a method of treating autoimmune diseases, rheumatism or rheumatoid arthritis is provided. This osteopontin antibody is useful in a diagnostic for rheumatism and a method of diagnosing rheumatism too.

Growing community of inventors

Hokkaido, Japan

Shigeyuki Kon